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Objectives: To assess the impact of Schedule H1 regulation notified and implemented in 2014 under the
amended rules of the Drugs and Cosmetics Act (DCA), 1940 on the sale of antimicrobials in the private sector in
India.
Methods: The dataset was obtained from the Indian pharmaceutical sales database, PharmaTrac. The outcome
measure was the sales volume of antimicrobials in standard units (SUs). A quasi-experimental research design—
interrupted time series analysis—was used to detect the impact of the intervention.
Results: We observed a substantial rise in antimicrobial consumption during 2008–18 in the private sector in
India, both for antimicrobials regulated under Schedule H1 as well as outside the regulation. Key results
suggested that post-intervention there was an immediate reduction (level change) in use of Schedule H1 antimi-
crobials by 10% (P"0.007), followed by a sustained decline (trend change) in utilization by 9% (P . 0.000)
compared with the pre-intervention trend. Segregated analysis on different antimicrobial classes suggests a
sharp drop (level changes) and sustained decline (trend changes) in utilization post-intervention compared with
the pre-intervention trend. Our findings remained robust on carrying out sensitivity analysis with the oral anti-
diabetics market as a control. Post-intervention, the average monthly difference between antimicrobials under
Schedule H1 and the control group witnessed an immediate increase of 16.3% (P"0.10) followed by a sustained
reduction of 0.5% (P"0.13) compared with the pre-intervention scenario.
Conclusions: Though the regulation had a positive impact in terms of reducing sales of antimicrobials notified
under the regulation, optimizing the effectiveness of such stand-alone policies will be limited unless accompa-
nied by a broader set of interventions.
Introduction
Globally, antimicrobial resistance (AMR) currently accounts for
about 700 000 deaths annually.1,2 Research suggests that wide-
spread and inappropriate use of antimicrobials is significantly
linked to growing AMR worldwide.3,4 This is particularly true for
low- and middle-income countries (LMICs) where overall anti-
microbial consumption as well as unnecessary antimicrobial
use has accelerated.5,6 Global evidence has suggested that anti-
microbial consumption rates in LMICs appear to converge towards
high-income economies for the period spanning 2000–15.7
Furthermore, it has been noted that the consumption of last-
resort antimicrobials such as carbapenems and polymyxins has
accelerated sharply in these countries in the same period. In India,
per capita consumption of antimicrobials has grown from 13.1
DDDs per thousand inhabitants per day (DID) in 2008 to 16.0
DID in 2012, and this increase has been primarily driven by the util-
ization of newer classes of antimicrobials such as carbapenems,
lincosamides, glycopeptides, cephalosporins and penicillins with
b-lactamase inhibitors.8
Resistance of pathogens to last-resort antimicrobials has been
reported in India, using diagnostic laboratory data for the years
spanning 2008–14.9 The problem of underuse, overuse and misuse
of antimicrobials remains an impediment to saving lives in the
country. Inappropriate antimicrobial use includes the use of anti-
microbials to treat viral conditions, the use of the incorrect class of
antimicrobials, the use of incorrect dosage or route of administra-
tion, and the lack of proper adherence to treatment. Antimicrobial
prescription and consumption rates in India continue to be lower
in comparison with European countries8 but prescription rates for
broad-spectrum b-lactam antimicrobials are significantly higher in
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India, especially among children. Nearly one-fifth of all antimicro-
bials prescribed in the country are for upper respiratory infections,
which rarely require treatment with an antimicrobial agent.
Frequent use of expensive, newer classes of antimicrobials as com-
pared with the older, more affordable ones in the Indian private
sector has also been reported.10,11
Inappropriate use of antimicrobials appears to be driven by
supply-side factors in the pharmaceutical market. During 2017, it
was reported that a single manufacturer produced penicillin G
(narrow-spectrum antimicrobial) compared with 135 companies
marketing cefixime (broad-spectrum antimicrobial).12 Other
supply-side factors include rampant prescribing and use of fixed-
dose combinations (FDCs) involving two or more antimicrobials.
For instance, it is estimated that 68% of FDCs containing antimicro-
bials on the Indian market have not been approved by the central
drug regulator.13 Besides, over-the-counter (OTC) availability of
antimicrobials at retail pharmacies and self-medication by
patients add to inappropriate antimicrobial use. A systematic re-
view of non-prescription use of antimicrobial medicines found that
such practices lead to adverse drug reactions.14 The same study
also reported a decline in antimicrobial use and resistance upon
the introduction of regulation. Interventions considered to reduce
AMR prevalence include, among others, improving sanitation, pub-
lic awareness campaigns, promoting new and rapid diagnostics
and developing new vaccines.15 One of the key interventions is to
improve surveillance through monitoring and reporting antimicro-
bial consumption. A 2018 WHO report called upon member coun-
tries to ensure responsible use by way of allowing prescription-only
antimicrobials.16
In India, the Drugs and Cosmetics Act (DCA), 1940 (and Drugs
and Cosmetics Rules, 1945) is the key legislation regulating the
import, production, sale, prescription and use of medicines.
Schedule H of the DCA governs the sale of prescription-only medi-
cines including antimicrobials. All medicines under Schedule H are
prescription only and cannot be purchased over the counter.
However, evidence from India suggests that in addition to non-
scheduled drugs, antimicrobials on Schedule H were also available
over the counter at private pharmacies without a prescription.17 In
2013, a new Schedule H1 was introduced under the amended
Drugs and Cosmetics Rules to regulate the sale and use of 46 drugs.
Schedule H1 was largely intended to regulate newer classes of
antimicrobials such as third- and fourth-generation cephalosporins,
besides certain habit-forming drugs and anti-TB drugs.18
Accordingly, Schedule H1 requires prescribers to record the prescrip-
tion and patient profile, and this record is expected to be preserved
for a period of 3 years. It also directs manufacturers to display labels
on the top-left corner of the packet with the symbol Rx, along with a
statutory warning with the caution not to use without medical
advice and not to be sold without a prescription by a Registered
Medical Practitioner. We investigated the impact of the Schedule H1
regulation notified in 2014 under the amended rules of the DCA,
1940 on the sale of antimicrobials in the private sector in India.
Materials and methods
Data
The dataset for this analysis was obtained from the Indian pharmaceutical
sales database, PharmaTrac, which is a market research company set up as
a joint venture between All Indian Origin Chemists and Distributors Ltd
(AIOCD Ltd) and Trikaal Mediinfotech Pvt Ltd. The dataset spans a
132 month period from January 2008 to December 2018. PharmaTrac data
are collected from a panel of 9000 stockists (about 60% of the total stock-
ists in the country) across 30 different regions of the country and extrapo-
lated to reflect the overall medicine sales in the Indian private-sector retail
segment. PharmaTrac datasets are utilized extensively by the Government
of India in regulating essential medicine prices.19 Medicines are classified
and arranged in the dataset based on the anatomical therapeutic chemical
(ATC) classification of the European Pharmaceutical Market Research
Association (EphMRA). This classification was employed to identify retail
sales of antimicrobials, especially Schedule H1 medicines, in the Indian pri-
vate sector. These belonged to two classes within the anti-infectives seg-
ment, i.e. systemic antimicrobials and antimycobacterials. Within the class
‘systemic antimicrobials’, we identified medicines in the subsegments
involving cephalosporins, fluoroquinolones, macrolides and similar types,
other b-lactams excluding penicillins and cephalosporins, such as mono-
bactams and carbapenems, and other antimicrobials. Within the class
‘antimycobacterials’, two subsegments were identified: anti-TB products
and drugs for the treatment of leprosy. This dataset does not capture
public-sector utilization of medicines in India, but it does capture the sales
of medicines prescribed in the public-sector facilities and bought by patients
at retail pharmacies in the private sector. Our analysis therefore focuses
exclusively on the impact of the policy on the Indian private-sector retail
sales of Schedule H1 antimicrobials. It may also be noted that, in value
terms, about 85%–90% of all medicine prescriptions in India occur in the
private sector, while the remainder are prescribed, procured and dispensed
in government health facilities.20
Intervention under study
The intervention of interest is the notification and subsequent implementa-
tion of Schedule H1 of the Drugs and Cosmetics Rules, 1945 (amended
2013). Though Schedule H medicines were already required to be sold with
the warning ‘to be sold by retail on the prescription of a Registered Medical
Practitioner only’ and labelled with the symbol NRx in red in the top-left
corner of the label, Schedule H1 medicines are supposed to be labelled with
the symbol Rx in red in the top-left corner of the label along with the
warning ‘it is dangerous to take this preparation except in accordance with
the medical advice’ and ‘not to be sold by retail without the prescription of a
Registered Medical Practitioner’ in a box with a red border. In addition, the
dispensing pharmacist is required to maintain a separate register wherein
identity of the patient, prescribing doctor’s contact information, name and
dispensed quantity of these medicines are recorded. Such a sales register
must be retained with the pharmacists for a 3 year period that can be
accessed by government drug inspectors during surprise checks.
Thirty-five formulations of antimicrobials were notified under Schedule
H1 (see Table S1, available as Supplementary data at JAC-AMR Online). Of
these, 33 were identified in PharmaTrac data. It must be noted that all the
different salt forms as well as FDCs containing these molecules came under
the ambit of Schedule H1 and were therefore coded into the dataset as
Schedule H1 medicines. Schedule H1 was implemented after 6 months
from notification, i.e. 1 March 2014 onwards.
Outcomes
The primary outcome measure for the study was sales volume of antimi-
crobials under Schedule H1 regulation in terms of standard units (SUs). SUs
are defined as the smallest dose of formulation, which can be one tablet or
capsule for oral solids and one vial or ampoule for injectable drugs. We
computed the combined sales volumes in SUs of all Schedule H1 antimicro-
bials for the time period under study and then converted sales volumes into
logarithmic form to investigate the change in sales volumes during pre-
and post-intervention periods. Antimicrobial sales volume was considered
a proxy for antimicrobial consumption for the purpose of this study due to
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Research design
We used interrupted time series,21 a quasi-experimental research design,
to measure the impact of Schedule H1 of the Drugs and Cosmetics Rules,
1945 (amended and notified on 30 August 2013) on antimicrobial utiliza-
tion in India. A reference market, oral anti-diabetics, which was outside this
regulation, was used as a control group to further strengthen our research
design.
Statistical analysis
We performed segmented linear regression analysis to detect the pre-
intervention trend, post-intervention level and trend change relative to the
pre-intervention level and trend of Schedule H1 antimicrobial utilization.
The dependent variable (Yt) appeared as ‘logarithm of sales volume’ of
Schedule H1 antimicrobials. ‘Time’ appeared as an independent variable. A
least-squares regression line was fitted to the two segments of the continu-
ous variable time and two binary variables were introduced to estimate the
immediate level change (variable name: intervention) and trend change
(variable name: time after intervention) after the intervention in the loga-
rithm of the sales volume of Schedule H1 antimicrobials (see Equation 1).
The Schedule H1 regulation parameter ‘intervention’ is a binary variable
taking the value ‘0’ for the 74 month pre-intervention period and the value
‘1’ for the 58 month post-intervention period starting March 2014, whereas
‘time after intervention’ is a continuous variable beginning March 2014.
Another dummy (d) was introduced to factor the role of seasonality in con-
sumption. Accordingly, the dummy variable is assigned a value ‘1’ for
3 months (August, September and October) each year. These months were
chosen to reflect the monsoon season in India. The choice of the seasonal
dummy is consistent with the findings of earlier studies.8 The segmented
regression analysis helped us statistically determine the change in the
intercept (b2) and the slope coefficients (b3) between the pre- and post-
intervention periods. a is the baseline intercept and et is the error term.
Yt ¼ aþ b1 time tþ b2 intervention tþ b3 time
after intervention tþ dþ et
(1)
We also introduced a counterfactual into the model, i.e. the trend in the
consumption of Schedule H1 antimicrobials in the post-intervention period
had the schedule not been notified. This was done by assuming that the
pre-intervention trend would have continued in the post-intervention
period had the intervention not been implemented. We checked the model
for autocorrelation with the help of the Durbin–Watson statistic and
reported autocorrelation and partial autocorrelation estimates and plots of
the residuals (see Figures S1, S2 and S3).We detected first-order autocorrel-
ation in our model and therefore altered it to the Prais–Winsten model
(Model 2) that makes use of the generalized least-squares method to esti-
mate parameters.
We further refined our model by excluding the adjustment period of
6 months between the date of notification, 30 August 2013, and the date
of implementation, 1 March 2014. As part of the sensitivity analysis, we ran
our models with a comparison group, i.e. oral anti-diabetics, which was out-
side the ambit of Schedule H1 regulation, to control for time-varying con-
founders and other policies that may be impacting intervention and control
groups. We ensured that those oral anti-diabetics that came under the
ambit of a separate price-regulation policy were excluded before using the
segment as a comparison group. This was done to eliminate any confound-
ing effect of price regulation. The analysis was carried out using STATA soft-
ware version 14.
Ethics
This study did not entail primary data collection. Secondary pharmaceutical
market data were used. We therefore did not require ethics approval for the
study.
Results
Our analysis suggests that antimicrobial sales by volume (including
antimycobacterials) have been steadily accelerating year on year,
with notable peaks reflecting seasonality in consumption, espe-
cially in the monsoon season (see Table 1 and Figure 1) in the pri-
vate retail sector in India during the study period (2008–18). A
similar trend was observed in prescription-only (Schedule H1) anti-
microbials until 2014, which thereafter remained constant for a
couple of years but declined in the later years. As a share, the
Schedule H1 antimicrobial sales that were accelerating in the pre-
intervention period remained stagnant at about 35% from 2014
onwards.
Segmented regression model results
Evidence from the segmented regression analysis (Model 1,
Table 2) suggests that post-intervention there was an immediate
reduction (level changes) in the utilization of Schedule H1 antimi-
crobials followed by a sustained decline of 9% as compared with
the pre-intervention trend. However, we detected first-order auto-
correlation in Model 1 (Figures S1, S2 and S3). We corrected for
autocorrelation by using the Prais–Winsten model (Model 2). The
direction and magnitude of the impact of the intervention
Table 1. Summary statistics, antimicrobial sales in India, 2008–18
Year
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Number of producers 611 605 609 511 461 447 585 588 576 586 574
Total antimicrobials 10.07 10.72 11.43 11.66 11.85 11.87 12.04 12.26 12.36 11.68 11.54
Schedule H1 antimicrobials 2.86 3.2 3.64 4 4.27 4.25 4.27 4.31 4.34 4.07 4.13
Share of Schedule H1 antimicrobials (%) 28.42 29.83 31.82 34.31 36.05 35.77 35.48 35.12 35.11 34.89 35.77
Single-ingredient antimicrobials 6.81 7.17 7.55 7.51 7.48 7.35 7.32 7.37 7.57 7.1 7.23
FDC antimicrobials 3.25 3.54 3.88 4.14 4.37 4.52 4.72 4.89 4.8 4.57 4.31
Share of FDC in antimicrobials (%) 32.31 33.06 33.95 35.53 36.91 38.12 39.18 39.87 38.79 39.17 37.35
Volumes are shown in billion SUs.
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remained more or less similar to previous estimates. Results from
this model suggest that post-intervention there was an immediate
reduction (level change) in the utilization of Schedule H1 antimi-
crobials by 10% (P"0.007), followed by a sustained decline (trend
change) of 9% (P . 0.000) as compared with the pre-intervention
trend.
As part of sensitivity analysis, we carried out another seg-
mented regression analysis (Model 3) with a control group—medi-
cines belonging to the oral anti-diabetics segment—which was
outside of this regulation. Table 2 and Figure 2 (Model 3) demon-
strate that in the pre-intervention period the average monthly
trend in the difference between antimicrobials under Schedule H1
and the control group was 1.9% (P"0.000). However, post-
intervention the average monthly difference between antimicro-
bials under Schedule H1 and the control group witnessed an im-
mediate increase (level change) followed by a sustained reduction
(trend change) as compared with the pre-intervention scenario,
but both changes were statistically insignificant.
Figure 2 presents a plot of fitted values of the two groups of
medicines—Schedule H1 antimicrobials (treatment group) and
oral anti-diabetics (control group)—in the actual (solid lines) and
counterfactual (dotted lines) scenarios. The counterfactual repre-
sents the scenario had the intervention (Schedule H1) not been
implemented. The vertical lines in the figure represent the imple-
mentation period (6 month period between the notification of
Schedule H1 and its implementation). The figure shows that in the
absence of regulation (the counterfactual scenario), Schedule H1
antimicrobial consumption would have witnessed a rising secular
trend (dotted red lines). However, as a result of the interventions
(the actual scenario), regulated antimicrobial utilization recorded a
steep decline (solid red lines). The comparison group too witnessed
a decline in utilization in the post-intervention period (solid blue
y = 0.0317x − 554.49
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Figure 1. Growth and seasonality in antimicrobial sales.
Table 2. Segmented regression model results
Variables
Model 1 Model 2 Model 3
coefficient P value (95% CI) coefficient P value (95% CI) coefficient P value (95%CI)
Time 0.008 0.000 (0.007–0.01) 0.008 0.000 (0.006–0.010) 0.019 0.000 (0.016–0.022)
Intervention
(level change)
#0.08 0.007 (#0.138 to #0.022) #0.1 0.054 (#0.203 to 0.002) 0.163 0.101 (#0.033 to 0.360)
Time after intervention
(trend change)
#0.009 0.00 (#0.010 to #0.007) #0.009 0.00 (#0.012 to #0.006) #0.005 0.126 (#0.010 to 0.001)
Seasonal dummy 0.246 0.000 (0.213–0.280) 0.155 0.000 (0.118–0.192) NA NA
Constant 19.18 0.000 (19.144–19.224) 19.19 0.000 (19.113–19.268) 18.09 0.000 (17.967–18.220)
Number of observations 126 126 126
pre-intervention 68 68 68
post-intervention 58 58 58
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line) in comparison with the counterfactual scenario (dotted blue
line). However, the decline was far more pronounced in the treat-
ment group (Schedule H1 antimicrobials) as compared with the
control group (oral anti-diabetics).
We further conducted formulation level and subtherapeutic
classwise analysis of level and trend change post-intervention.
Table 3 highlights those results. Schedule H1 formulations belong-
ing to the cephalosporins, fluoroquinolones and anti-TB classes
witnessed a sharp drop and sustained decline in utilization
post-intervention. The only exception was Schedule H1 formula-
tions in the class of ‘other b-lactam antimicrobials’, which saw a
sharp increase, followed by a small but sustained rise in utilization.
The antimicrobials outside Schedule H1 witnessed a sharp rise in
use immediately after the intervention. The increase, however,
was insignificant. For instance, broad-spectrum penicillin formula-
tions, as well as tetracyclines and combinations that were outside
Schedule H1, witnessed a sudden rise followed by a sustained drop
in utilization in the post-intervention period in comparison with the
pre-intervention period, whereas medium- and narrow-spectrum
penicillins, as well as aminoglycosides that were also outside
Schedule H1, reported a sudden and sustained drop in utilization in
the post-intervention period.
Discussion
This piece of research is, to our knowledge, the first attempt to sys-
tematically report the impact of Schedule H1, a stringent version
of Schedule H of Drugs and Cosmetics Rules, 1945 (amended
2013), which governs the sales and dispensing of prescription-only
medicines in India. Using an interrupted time series regression
model, we report the impact of Schedule H1 regulation on utiliza-
tion of notified antimicrobials in the Indian private sector from
2008 to 2018. We observed that nearly 600 manufacturers were
marketing antimicrobials in India, reflecting a competitive market.
However, FDCs involving one or more antimicrobials accounted for
over one-third of antimicrobials sold in the market.
During our study period, a substantial rise in antimicrobial con-
sumption was observed in the private sector in India, both for
Schedule H1 and non-Schedule H1 antimicrobials. In the monsoon
season, antimicrobial sales volume in the country peaked on ac-
count of various bacterial and viral infections. Earlier studies in
India have shown that although overall utilization of antimicro-
bials was relatively lower vis-à-vis European standards when
measured as DID, they demonstrated wider usage of third- and
fourth-generation antimicrobials, suggesting inappropriate use.8
We observed a steep decline in the sales volume of Schedule
H1 antimicrobials in the 6 month period between the notification
of Schedule H1 and its implementation, which suggests that the
suppliers must have been withdrawing the stocks from the market
to re-label the medicine packs to comply with the government’s
directive. This period was excluded from the model to remove its
confounding effect on our results. We found a significant decline
in both level and trend of antimicrobial use after Schedule
H1 restrictions were imposed in 2014. A negative direction of
post-intervention level and trend changes as compared with pre-
intervention level and trend was observed among cephalosporins,
fluoroquinolones and anti-TB drugs, suggesting a sharp drop and
sustained decline in sales volume post-intervention. The segment
‘other b-lactam antimicrobials’, which includes carbapenems and
monobactams, witnessed a sharp immediate increase in sales
after the intervention compared with the pre-intervention period
followed by a small sustained increase in the trend. The sharp but
insignificant increase observed for non-Schedule H1 antimicrobials
could possibly indicate a small substitution effect of retail sales
from restricted to non-restricted antimicrobials.
21
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Figure 2. Actual and counterfactual medicine consumption for regulated antimicrobials and control drugs. The comparison (control) group is oral
anti-diabetics in the Indian pharmaceutical market.
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Similar laws restricting OTC sales of antimicrobials in 2010 in
Brazil and Mexico were observed to have resulted in a decline in
the overall usage pattern. Specifically, penicillin, sulphonamide
and macrolide usage levels indicated in terms of DDD declined in
Brazil after the intervention, while in Mexico the consumption of
penicillin and sulphonamides was found to have declined signifi-
cantly.22 Another study from these countries suggested that re-
striction of OTC sales of antimicrobials resulted in unintended
consequences by increasing the use of symptomatic drugs includ-
ing those for colds and coughs and non-steroidal anti-inflamma-
tory drugs (NSAIDs).23 A Swedish study revealed a decline in
antimicrobial use among pre-school children, as they were less
commonly prescribed, but reported an associated increase in
paediatric paracetamol sales, suggesting that symptomatic self-
treatment had increased.24
A key limitation of this study is the inclusion of only private-
sector sales data for antimicrobial products. However, it may be
noted that in government health facilities such restrictions are su-
perfluous because both procurement and prescriptions are gov-
erned by the Essential Medicines List. Moreover, as per the Indian
constitution, health service delivery in the public sector is under
state government and there are about 35 states in India. No single
and uniform database exists or is available for public scrutiny.
Furthermore, in value terms about 85%–90% of all medicine pre-
scriptions in India occur in the private sector, while the remainder
are prescribed, procured and dispensed in government health
facilities.20 Thus, the role of an OTC sales ban of antimicrobials is
largely relevant to the private sector.
It is also recognized that regulations prohibiting antimicrobial
OTC sales may also lead to unintended consequences by means of
a substitution effect. Antimicrobials are often prescribed without
proper diagnosis, especially in LMICs. For instance, antimicrobials
are commonly prescribed for infections such as upper respiratory
tract infections that are viral and self-limiting in nature and do not
require them. Patients also tend to self-medicate for conditions
such as common cold and cough, for symptomatic relief. Although
such substitution is potentially expected, the regulation under
study is aimed at restricting the use of third- and fourth-
generation antimicrobials. It is equally plausible that the use of
non-restrictive first- and second-generation antimicrobials would
have increased due to this regulation.
Conclusions
Policy instruments are often deployed to influence the demand
and supply of health products and services, through direct or indir-
ect controls. The primary objective of Schedule H1 regulation was
to restrict the use of antimicrobials, especially the broad-spectrum
antimicrobials, using cautionary labels and symbols on the pack-
ages to increase awareness among patients, dispensers and pre-
scribers and encourage them to act with caution. However, the
effectiveness of such stand-alone policies could be limited unless
accompanied by other interventions. Effective regulation at every
stage including import, production, distribution, procurement, pre-
scription, dispensing and use is required. For instance, market au-
thorization of an antimicrobial product must be by a single















Classes with Schedule H1 formulations
cephalosporins 0.012 (0.000) #0.094 (0.199) #0.012 (0.000) 18.538 (0.000) 0.989 47
fluoroquinolones 0.002 (0.093) #0.123 (0.055) #0.005 (0.007) 17.256 (0.000) 0.991 9
other b-lactam
antimicrobials
0.014 (0.000) 0.280 (0.005) 0.002 (0.470) 13.135 (0.000) 0.988 6
anti-TB 0.002 (0.001) #0.120 (0.003) #0.006 (0.000) 18.110 (0.000) 0.996 17
total Schedule H1
antimicrobials
0.008 (0.000) #0.08 (0.0054) #0.009 (0.000) 19.184 (0.000) 0.986 83
Classes without Schedule H1 formulations
broad-spectrum penicillins 0.003 (0.002) 0.021 (0.703) #0.002 (0.296) 18.848 (0.000) 0.994 31
medium- and
narrow-spectrum penicillins
0.006 (0.119) #0.028 (0.907) #0.007 (0.253) 16.742 (0.000) 0.947 7
aminoglycosides 0.003 (0.013) #0.024 (0.759) #0.023 (0.285) 16.230 (0.000) 0.991 8
tetracycline and combinations 0.004 (0.002) 0.045 (0.500) #0.011 (0.000) 17.964 (0.000) 0.981 12
total antimicrobials
outside Schedule H1
0.001 (0.089) 0.009 (0.843) #0.000 (0.898) 20.318 (0.000) 0.992 136
Schedule H1 cephalosporins include cefixime, cefdinir, cefpodoxime, ceftriaxone, ceftazidime, cefoperazone, cefepime, ceftizoxime, cefpirome, cefe-
tamet, cefotaxime, cefditoren, ceftibuten and their combinations. Schedule H1 fluoroquinolones include balofloxacin, gemifloxacin, levofloxacin,
moxifloxacin, prulifloxacin, sparfloxacin and their combinations. Schedule H1 ‘other b-lactam antibacterials’ include ertapenem, faropenem, imipen-
em, meropenem and their combinations. Schedule H1 anti-TB drugs include capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazina-
mide, rifabutin, rifampicin and their combinations. ‘Total antimicrobials outside Schedule H1’ includes all antimicrobials belonging to classes not
containing Schedule H1 antimicrobials and also antimicrobials left out of Schedule H1 in classes that include some Schedule H1 antimicrobials such
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government agency. This is critical given the fact that around 40%
of all antimicrobial products sold in India are FDCs. Another poten-
tial solution lies in transforming the current landscape of the
health sector towards universal health coverage instead of being
dominated by a system of private provisioning and financing. As
long as the health sector is financed by households directly, per-
verse incentives will remain among producers, prescribers and
dispensers.
Funding




Table S1 and Figures S1 to S3 are available as Supplementary data at JAC-
AMR Online.
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